Factor Model (net +0.5)
Factor Model
net +0.5 1.6 / 10UBS doubles target to $4; Wells Fargo holds $14 bull case
Watch: Next quarterly prescriber uptake and patient starts will determine if Wells Fargo's bull case or UBS's caution is justified—adoption velocity is the bridge between current losses and profitability.
UBS raised its price target to $4 from $2 but kept a neutral rating, signaling upside to current levels despite cautious positioning. Wells Fargo remains bullish with a $14 target and buy rating, a 173% spread to UBS's view reflecting deep disagreement on Amtagvi's commercial trajectory. The stock rallied 12% to $5.13 on March 6 as revenue jumped 60.6% YoY to $263.5M in 2025, though net losses widened 5% to $390.98M.
UBS's target raise validates real-world clinical data momentum but the neutral rating suggests limited near-term catalyst clarity, while Wells Fargo's aggressive $14 target depends on Amtagvi adoption accelerating faster than current burn rates support. Analyst disagreement this wide signals execution risk remains the key variable.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when IOVA changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.